These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 37387533)

  • 21. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
    Subbiah V; Iannotti NO; Gutierrez M; Smith DC; Féliz L; Lihou CF; Tian C; Silverman IM; Ji T; Saleh M
    Ann Oncol; 2022 May; 33(5):522-533. PubMed ID: 35176457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond.
    Uson Junior PLS; Borad MJ
    Expert Opin Investig Drugs; 2022 Jan; 31(1):125-131. PubMed ID: 34904492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors.
    Rizzo A
    Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34066684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma.
    Rizzo A; Ricci AD; Brandi G
    Cancer Treat Res Commun; 2021; 27():100337. PubMed ID: 33611090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma.
    Lamarca A; Ostios L; McNamara MG; Garzon C; Gleeson JP; Edeline J; Herrero A; Hubner RA; Moreno V; Valle JW
    Cancer Treat Rev; 2023 Dec; 121():102627. PubMed ID: 37925878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations.
    Varghese AM; Patel J; Janjigian YY; Meng F; Selcuklu SD; Iyer G; Houck-Loomis B; Harding JJ; O'Reilly EM; Abou-Alfa GK; Lowery MA; Berger MF
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives.
    Rizzo A; Ricci AD; Brandi G
    Expert Opin Investig Drugs; 2021 Apr; 30(4):317-324. PubMed ID: 33054456
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Angerilli V; Fornaro L; Pepe F; Rossi SM; Perrone G; Malapelle U; Fassan M
    Pathologica; 2023 Apr; 115(2):71-82. PubMed ID: 37017301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors.
    Wu T; Jiang X; Zhang X; Wu B; Xu B; Liu X; Zheng L; Wang Y
    Cancer Control; 2021; 28():1073274821989314. PubMed ID: 33618536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
    Borad MJ; Champion MD; Egan JB; Liang WS; Fonseca R; Bryce AH; McCullough AE; Barrett MT; Hunt K; Patel MD; Young SW; Collins JM; Silva AC; Condjella RM; Block M; McWilliams RR; Lazaridis KN; Klee EW; Bible KC; Harris P; Oliver GR; Bhavsar JD; Nair AA; Middha S; Asmann Y; Kocher JP; Schahl K; Kipp BR; Barr Fritcher EG; Baker A; Aldrich J; Kurdoglu A; Izatt T; Christoforides A; Cherni I; Nasser S; Reiman R; Phillips L; McDonald J; Adkins J; Mastrian SD; Placek P; Watanabe AT; Lobello J; Han H; Von Hoff D; Craig DW; Stewart AK; Carpten JD
    PLoS Genet; 2014 Feb; 10(2):e1004135. PubMed ID: 24550739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality.
    Jain NK; Tailang M; Thangavel N; Makeen HA; Albratty M; Najmi A; Alhazmi HA; Zoghebi K; Alagusundaram M; Jain HK; Chandrasekaran B
    Acta Pharm; 2024 Mar; 74(1):1-36. PubMed ID: 38554385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.
    Wang Y; Ding X; Wang S; Moser CD; Shaleh HM; Mohamed EA; Chaiteerakij R; Allotey LK; Chen G; Miyabe K; McNulty MS; Ndzengue A; Barr Fritcher EG; Knudson RA; Greipp PT; Clark KJ; Torbenson MS; Kipp BR; Zhou J; Barrett MT; Gustafson MP; Alberts SR; Borad MJ; Roberts LR
    Cancer Lett; 2016 Sep; 380(1):163-73. PubMed ID: 27216979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
    Javle M; King G; Spencer K; Borad MJ
    Oncologist; 2023 Nov; 28(11):928-943. PubMed ID: 37390492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel precision therapies for cholangiocarcinoma: an overview of clinical trials.
    Uson Junior PLS; Bearss J; Babiker HM; Borad MJ
    Expert Opin Investig Drugs; 2023 Jan; 32(1):69-75. PubMed ID: 36714945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Not Available].
    Mas L; Perrier A; Coulet F; Bachet JB
    Bull Cancer; 2022 Nov; 109(11S):11S28-11S34. PubMed ID: 36535760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unmet needs in the treatment of intrahepatic cholangiocarcinoma harboring
    Beri N
    Future Oncol; 2022 Apr; 18(11):1391-1402. PubMed ID: 35081733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Robust Response to Futibatinib in a Patient With Metastatic FGFR-Addicted Cholangiocarcinoma Previously Treated Using Pemigatinib.
    Rengan AK; Denlinger CS
    J Natl Compr Canc Netw; 2022 Apr; 20(5):430-435. PubMed ID: 35378504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The future of fibroblast growth factor receptor inhibitors and mechanisms of resistance for cholangiocarcinoma.
    Ruff SM; Roychowdhury S; Pawlik TM
    Expert Opin Pharmacother; 2023 May; 24(7):779-788. PubMed ID: 37042129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion.
    Storandt MH; Jin Z; Mahipal A
    Expert Rev Anticancer Ther; 2022 Dec; 22(12):1265-1274. PubMed ID: 36408971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy.
    Brown ZJ; Ruff SM; Pawlik TM
    Expert Rev Anticancer Ther; 2023 Mar; 23(3):257-264. PubMed ID: 36744395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.